Coronavirus | Ayush Ministry lens on Baba Ramdev’s COVID-19 cure
Bindu Shajan PerappadanJacob KoshyNEW DELHI, JUNE 23, 2020 19:50 IST
UPDATED: JUNE 23, 2020 22:51 IST
SHARE ARTICLE 38PRINTA A A
A photo of the kit released by Patanjali. Photo: Twitter
A photo of the kit released by Patanjali. Photo: Twitter
Centre asks Patanjali to stop advertising the drug, seeks details on formulation.
Hours after yoga guru Baba Ramdev unveiled an Ayurvedic medicine — ‘Coronil and Swasari’ — on Tuesday, claiming that clinical trials on COVID-19 affected patients had shown favourable results, the Central government asked Patanjali Ayurved Limited to stop advertising the drug and sought details on its claimed “successful trial and cure”.
Also read: HC directs ICMR to verify claim on effectiveness of drug in COVID-19 treatment
In a statement issued by the Ministry of Ayush on the claims made by Haridwar (Uttrakhand)-based Patanjali Ayurved in treating COVID-19, the Ministry noted that it had taken cognisance of the news being recently flashed on its drug by the company. Facts of the claim related to the drug and details of the stated scientific study are not known to the Ministry, the statement said.
List of details
Patanjali Ayurved has been asked to provide, at the earliest, details of the name and composition of the medicines being claimed as successful in COVID-19 treatment; site(s)/ hospital(s) where the research study was conducted; the protocol, sample size, Institutional Ethics Committee clearance, Clinical Trials Registry-India (CTRI) registration, and results data of the study, and to stop advertising/publicising such claims till the issue had been duly examined.
Also read: Coronavirus | Highly irresponsible on the part of AYUSH Ministry to prescribe Unani medicines
The Ministry has also requested the concerned State Licensing Authority of the Uttarakhand government to provide copies of the license and product approval details of Ayurvedic medicines being claimed as useful in the treatment of COVID -19.
Regulated by Act
“Also, the concerned Ayurvedic drug manufacturing company has been informed that such advertisements of drugs including Ayurvedic medicines are regulated under the provisions of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and Rules thereunder and the directives issued by the Central Government in the wake of COVID outbreak. The Ministry had also issued a Gazette Notification on April 21, 2020 stating the requirements and the manner in which research studies on COVID-19 with Ayush interventions/medicines should be undertaken,’’ the Ministry said.
‘100 patients’
Meanwhile, scientists associated with the trial said they had not yet published the results. Dr. Abhishekh Sharma, Assistant Professor of Medicine, National Institute of Medical Sciences, and among those who supervised the trial, said that 100 patients, who had tested positive for the virus, were recruited for the trial. Of them, 50 were given the medicine and five dropped out midway. The remaining 50 were administered a placebo.
Also read: Homeopathy drug untested for efficacy against COVID-19 widely distributed in Mumbai
“69% of the 45, when tested on the third day, were found clear of the virus and half of those on the placebo recovered,” said Dr. Sharma. That works out to 31 of those on the treatment tested negative, and 25 of those on placebo tested negative.
No other details on the profiles of the COVID-19 positive persons — the degree of sickness in those who enrolled for the trial, their age, whether they were on other medication prior to enrolment — were immediately available.
Clinical trial registry
A check on the clinical trial registry, where all trials must be registered, showed that a wide spectrum of patients were solicited. They were “asymptomatic, mildly symptomatic, moderately symptomatic and those aged 15-80”. The original aim of the study was to check the status of patients at day 3, day 7 and day 14, and whether they had improved immunological parameters due to the medicine. The medicine regime involved are the Tablet Swasari Ras (500 mg), Tablet Pure Ashwagandha Extract (500 mg), Tablet Pure Giloy Extract (500 mg), Tablet Pure Tulsi Extract (500 mg) and Anu Taila (nasal drop), according to information on the clinical trial website.
Coronavirus | Highly irresponsible on the part of AYUSH Ministry to prescribe Unani medicines
R. PrasadJANUARY 30, 2020 16:39 IST
UPDATED: JANUARY 30, 2020 16:41 IST
SHARE ARTICLE 8PRINTA A A
Passengers from China wearing masks to prevent a new coronavirus get fever check upon their arrival at Incheon International Airport in Incheon, South Korea.
Passengers from China wearing masks to prevent a new coronavirus get fever check upon their arrival at Incheon International Airport in Incheon, South Korea. | Photo Credit: Reuters
None of the medicines mentioned has ever undergone any form of clinical validation.
At a time when the number of novel coronavirus cases has crossed 7,700 — with deaths at 170 in China alone — and with the virus having spread to 20 countries/regions, the Ministry of Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy (AYUSH) has once again resorted to dishing out a dangerous prescription to people who might be infected with the virus.
In a press release circulated on Wednesday, the Ministry recommended certain Unani medicines for “symptomatic management of novel coronavirus” and certain Ayurveda and homeopathy medicines to help prevent coronavirus infection.
Nearly a month after China intimated the World Health Organization about the novel virus, no drugs to specifically target the virus are currently available and no candidate drugs are at any stage of clinical trial.
In the absence of specific drugs to treat the novel coronavirus, patients are only provided with symptomatic treatment, including making sure that patients get enough oxygen so that they survive long enough for the immune system to fight the disease on its own.
Not only is the recommendation by the Ministry highly irresponsible and dangerous but it also runs counter to the Ministry of Health and Family Welfare’s current practice of quickly isolating even suspected cases to prevent the spread of the virus and providing them with symptomatic treatment if found infected.
None of the medicines mentioned in the release has ever undergone any form of clinical validation. They have not been tested on people infected with the novel virus to study their ability to provide any kind of relief or prevent infection, either. Yet, the AYUSH Ministry has no hesitation in recommending the untested medicines to treat the virus, about which not much is known so far.
Symptoms not listed
Even as the Ministry issued a prescription to symptomatically manage infected people with Unani medicines, it has not cared to list out the symptoms that people infected with the novel virus exhibit or mention which medicines should be taken to treat which symptom.
People infected with the novel virus exhibit a wide range of symptoms. While most people exhibit milder symptoms akin to common cold such as fever and cough, about one in five manifest severe illness, including pneumonia and respiratory failure. Much like in the case of the Middle East Respiratory Syndrome caused by another coronavirus, some patients have been said to have had gastrointestinal symptoms, including diarrhoea.
By listing out the Unani medicines and asking people to use them for symptomatic management of the infection, the AYUSH Ministry is in fact encouraging people to self-medicate, which by itself is alarming. The press release is a mishmash of information put together in haste. While detailing Ayurveda medicines, it clearly states that the “advocacy is for information only and shall be adopted in consultation with registered Ayurveda practitioners only”, but no such cautionary note is found for Unani and homeopathy medicines.
With no evidence that the medicines would indeed provide even symptomatic relief, self-medication outside the healthcare system would put close contacts at grave risk of getting infected. After all, human-to-human transmission from infected cases to close contacts has been documented in China and other countries and even fourth-generation transmission has been recorded in Wuhan city, the epicentre of the disease outbreak in China.
Is the AYUSH Ministry aware of the kind of precautions that need to be taken while attending to people with the infection? Is it even aware that 16 healthcare workers who had been wearing all the mandatory protective gear while treating the infected cases fell ill themselves?
So when a passenger exhibiting symptoms suggestive of infection with the novel coronavirus is found at one of the 20 airports where thermal screening has been undertaken, will she be immediately quarantined and admitted to a hospital for further testing/treatment or will she be allowed to exercise her freedom to be treated at home with Unani medicines?
This should be reminder that the Health Ministry and AYUSH Ministry cannot afford to work at cross purposes.
పతంజలి కరోనా మందుకు బ్రేక్!
Jun 23, 2020, 19:22 IST
corona drug : Ministry of AYUSH asks for research data on
Patanjali Coronil - Sakshi
పూర్తి వివరాలు సమర్పించండి : ఆయుష్ మంత్రిత్వ శాఖ
అప్పటివరకూ ప్రచారాన్ని ఆపండి
సాక్షి, న్యూఢిల్లీ : కరోనా మహమ్మారి నివారణకు ఆయుర్వేద
మందును లాంచ్ చేసిన యోగా గురు రాందేవ్ నేతృత్వంలోని
పతంజలి సంస్థకు ఆదిలోనే అడ్డుకట్ట పడింది. ఆయుర్వేద
ఔషధం కరోనిల్ ప్రారంభానికి ముందు నిర్వహించిన పరిశోధనల
పూర్తి వివరాలు సమర్పించాలని కేంద్ర ఆయుష్ మంత్రిత్వ శాఖ
పతంజలి సంస్థను ఆదేశించింది. అంతేకాదు అప్పటివరకూ
ఎలాంటి ప్రచారాన్ని చేపట్టవద్దని కూడా మంత్రిత్వ శాఖ ఒక
పత్రికా ప్రకటనలో వెల్లడించింది. పతంజలి చెబుతున్న
అంశాలపై వాస్తవాలు, శాస్త్రీయ అధ్యయన వివరాలు మంత్రిత్వ
శాఖకు తెలియదని పేర్కొంది. ('కరోనిల్' 80 శాతం సక్సెస్ను
చూపించింది)
పతంజలి అట్టహాసంగా కరోనిల్ మందును ప్రారంభించిన కొన్ని
గంటల్లోనే ఆయుష్ మంత్రిత్వ శాఖ ఈ మందుకు సంబంధించి
కీలక ప్రకటన చేసింది. కోవిడ్-19 నివారణకు గాను పతంజలి
తయారు చేసిన ఆయుర్వేద మందును ఏ మోతాదులో, ఏయే
ఆసుపత్రిలలో పరిశీలించారు, సంబంధిత పరిశోధన ఫలితాల
తాజా డేటా, ఇనిస్టిట్యూషనల్ ఎథిక్స్ కమిటీ క్లియరెన్స్, సీటీఆర్ఐ
రిజిస్ట్రేషన్ వివరాలను తమకు అందించాలని మంత్రిత్వ శాఖ
కోరింది. వీటిని సమగ్రంగా పరిశీలించేంతవరకు ప్రచారాన్ని
ఆపాలని పతంజలి సంస్థను ఆదేశించింది. దీంతోపాటు కరోనిల్
తయారీకి మంజూరు చేసిన లైసెన్స్ కాపీలు, అనుమతి
వివరాలను అందించాలని మంత్రిత్వ శాఖ ఉత్తరాఖండ్
ప్రభుత్వాన్ని కోరింది. పతంజలి ప్రధాన కార్యాలయం హరిద్వార్లో
ఉంది, ఇది ఉత్తరాఖండ్ అధికార పరిధిలోకి వస్తుంది.
రాజస్థాన్ జైపూర్ నిమ్స్ వైద్యులతో పాటు పలువురు శాస్త్త్రవేత్తల
సహకారంతో 150కి పైగా ఔషధ మూలికలతో కరోనిల్ ఔషదాన్ని
రూపొందించామని పతంజలి సంస్థ ప్రకటించింది. క్లినికల్
కంట్రోల్ స్టడీ, క్లినికల్ కంట్రోల్ ట్రయల్ చేశాకే తాము కరోనిల్
మందును మార్కెట్లో విడుదల చేశామని రాందేవ్ వెల్లడించారు.
తమ మందు వాడిన కరోనా వైరస్ రోగులలో ఎక్కువ మంది 14
రోజుల్లో, దాదాపు 80 శాతం కోలుకున్నారని పతంజలి సహ
వ్యవస్థాపకుడు బాలకృష్ణ ప్రకటించిన సంగతి తెలిసిందే. కాగా
భారతదేశంలో 425,000 మందికి పైగా కరోనావైరస్ బారిన పడగా,
14,000 మంది మరణించారు. ప్రపంచవ్యాప్తంగా కరోనా బాధితుల
సంఖ్య తొమ్మిది మిలియన్లను దాటింది. మరణాల సంఖ్య 470,000
పైకి చేరుకుంది.
'కరోనిల్' 80 శాతం సక్సెస్ను చూపించింది
Jun 23, 2020, 12:20 IST
Ramdev To Launch 'Coronil' For Covid-19 Treatment Today - Sakshi
న్యూఢిల్లీ: కరోనా వ్యాక్సిన్ ను తయారు చేయడానికి ప్రపంచ దేశాలన్నీ అనేక ప్రయత్నాలు చేస్తున్నాయి. ఇప్పటికే 13 రకాల వ్యాక్సిన్లు మనుషులపై ప్రయోగించారు. మరో 120 కి పైగా సంస్థలు ఈ మందు తయారీలో నిమగ్నమయ్యాయి. తాజాగా యోగా గురువు బాబా రామ్దేవ్కు చెందిన పతంజలి ఆయుర్వేద సంస్థ కరోనా నివారణకు 'కరోనిల్' అనే ఆయుర్వేద ఔషదాన్ని కనుగొన్నట్లు ప్రకటించింది.
ఈ మేరకు పతంజలి యోగ్పీఠ్ సహవ్యవస్థాపకుడు ఆచార్య బాలకృష్ణ ట్విటర్ ద్వారా పేర్కొన్నారు. పతంజలి సంస్థ తయారుచేసిన ఔషదం 80 శాతం సక్సెస్ను చూపించినట్లు తెలిపారు. దీనికి సంబంధించిన పూర్తి వివరాలు మంగళవారం మధ్యాహ్నం హరిద్వార్లోని పతంజలి యోగ్పీఠ్లో ఏర్పాటు చేసే మీడియా సమావేశంలో వెల్లడించనున్నట్లు బాలకృష్ణ తన ట్విటర్ ఖాతాలో పేర్కొన్నారు. చదవండి: 'కరోనా నివారణకు ప్రత్యేక వ్యాక్సిన్'
Proud launch of first and foremost evidence-based ayurvedic medicine for #corona contagion, #SWASARI_VATI, #CORONIL, is scheduled for tomorrow at 12 noon from #Patanjali Yogpeeth Haridwar🙏🏻 pic.twitter.com/K7uU38Kuzl
— Acharya Balkrishna (@Ach_Balkrishna) June 22, 2020
Bindu Shajan PerappadanJacob KoshyNEW DELHI, JUNE 23, 2020 19:50 IST
UPDATED: JUNE 23, 2020 22:51 IST
SHARE ARTICLE 38PRINTA A A
A photo of the kit released by Patanjali. Photo: Twitter
A photo of the kit released by Patanjali. Photo: Twitter
Centre asks Patanjali to stop advertising the drug, seeks details on formulation.
Hours after yoga guru Baba Ramdev unveiled an Ayurvedic medicine — ‘Coronil and Swasari’ — on Tuesday, claiming that clinical trials on COVID-19 affected patients had shown favourable results, the Central government asked Patanjali Ayurved Limited to stop advertising the drug and sought details on its claimed “successful trial and cure”.
Also read: HC directs ICMR to verify claim on effectiveness of drug in COVID-19 treatment
In a statement issued by the Ministry of Ayush on the claims made by Haridwar (Uttrakhand)-based Patanjali Ayurved in treating COVID-19, the Ministry noted that it had taken cognisance of the news being recently flashed on its drug by the company. Facts of the claim related to the drug and details of the stated scientific study are not known to the Ministry, the statement said.
List of details
Patanjali Ayurved has been asked to provide, at the earliest, details of the name and composition of the medicines being claimed as successful in COVID-19 treatment; site(s)/ hospital(s) where the research study was conducted; the protocol, sample size, Institutional Ethics Committee clearance, Clinical Trials Registry-India (CTRI) registration, and results data of the study, and to stop advertising/publicising such claims till the issue had been duly examined.
Also read: Coronavirus | Highly irresponsible on the part of AYUSH Ministry to prescribe Unani medicines
The Ministry has also requested the concerned State Licensing Authority of the Uttarakhand government to provide copies of the license and product approval details of Ayurvedic medicines being claimed as useful in the treatment of COVID -19.
Regulated by Act
“Also, the concerned Ayurvedic drug manufacturing company has been informed that such advertisements of drugs including Ayurvedic medicines are regulated under the provisions of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and Rules thereunder and the directives issued by the Central Government in the wake of COVID outbreak. The Ministry had also issued a Gazette Notification on April 21, 2020 stating the requirements and the manner in which research studies on COVID-19 with Ayush interventions/medicines should be undertaken,’’ the Ministry said.
‘100 patients’
Meanwhile, scientists associated with the trial said they had not yet published the results. Dr. Abhishekh Sharma, Assistant Professor of Medicine, National Institute of Medical Sciences, and among those who supervised the trial, said that 100 patients, who had tested positive for the virus, were recruited for the trial. Of them, 50 were given the medicine and five dropped out midway. The remaining 50 were administered a placebo.
Also read: Homeopathy drug untested for efficacy against COVID-19 widely distributed in Mumbai
“69% of the 45, when tested on the third day, were found clear of the virus and half of those on the placebo recovered,” said Dr. Sharma. That works out to 31 of those on the treatment tested negative, and 25 of those on placebo tested negative.
No other details on the profiles of the COVID-19 positive persons — the degree of sickness in those who enrolled for the trial, their age, whether they were on other medication prior to enrolment — were immediately available.
Clinical trial registry
A check on the clinical trial registry, where all trials must be registered, showed that a wide spectrum of patients were solicited. They were “asymptomatic, mildly symptomatic, moderately symptomatic and those aged 15-80”. The original aim of the study was to check the status of patients at day 3, day 7 and day 14, and whether they had improved immunological parameters due to the medicine. The medicine regime involved are the Tablet Swasari Ras (500 mg), Tablet Pure Ashwagandha Extract (500 mg), Tablet Pure Giloy Extract (500 mg), Tablet Pure Tulsi Extract (500 mg) and Anu Taila (nasal drop), according to information on the clinical trial website.
Coronavirus | Highly irresponsible on the part of AYUSH Ministry to prescribe Unani medicines
R. PrasadJANUARY 30, 2020 16:39 IST
UPDATED: JANUARY 30, 2020 16:41 IST
SHARE ARTICLE 8PRINTA A A
Passengers from China wearing masks to prevent a new coronavirus get fever check upon their arrival at Incheon International Airport in Incheon, South Korea.
Passengers from China wearing masks to prevent a new coronavirus get fever check upon their arrival at Incheon International Airport in Incheon, South Korea. | Photo Credit: Reuters
None of the medicines mentioned has ever undergone any form of clinical validation.
At a time when the number of novel coronavirus cases has crossed 7,700 — with deaths at 170 in China alone — and with the virus having spread to 20 countries/regions, the Ministry of Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy (AYUSH) has once again resorted to dishing out a dangerous prescription to people who might be infected with the virus.
In a press release circulated on Wednesday, the Ministry recommended certain Unani medicines for “symptomatic management of novel coronavirus” and certain Ayurveda and homeopathy medicines to help prevent coronavirus infection.
Nearly a month after China intimated the World Health Organization about the novel virus, no drugs to specifically target the virus are currently available and no candidate drugs are at any stage of clinical trial.
In the absence of specific drugs to treat the novel coronavirus, patients are only provided with symptomatic treatment, including making sure that patients get enough oxygen so that they survive long enough for the immune system to fight the disease on its own.
Not only is the recommendation by the Ministry highly irresponsible and dangerous but it also runs counter to the Ministry of Health and Family Welfare’s current practice of quickly isolating even suspected cases to prevent the spread of the virus and providing them with symptomatic treatment if found infected.
None of the medicines mentioned in the release has ever undergone any form of clinical validation. They have not been tested on people infected with the novel virus to study their ability to provide any kind of relief or prevent infection, either. Yet, the AYUSH Ministry has no hesitation in recommending the untested medicines to treat the virus, about which not much is known so far.
Symptoms not listed
Even as the Ministry issued a prescription to symptomatically manage infected people with Unani medicines, it has not cared to list out the symptoms that people infected with the novel virus exhibit or mention which medicines should be taken to treat which symptom.
People infected with the novel virus exhibit a wide range of symptoms. While most people exhibit milder symptoms akin to common cold such as fever and cough, about one in five manifest severe illness, including pneumonia and respiratory failure. Much like in the case of the Middle East Respiratory Syndrome caused by another coronavirus, some patients have been said to have had gastrointestinal symptoms, including diarrhoea.
By listing out the Unani medicines and asking people to use them for symptomatic management of the infection, the AYUSH Ministry is in fact encouraging people to self-medicate, which by itself is alarming. The press release is a mishmash of information put together in haste. While detailing Ayurveda medicines, it clearly states that the “advocacy is for information only and shall be adopted in consultation with registered Ayurveda practitioners only”, but no such cautionary note is found for Unani and homeopathy medicines.
With no evidence that the medicines would indeed provide even symptomatic relief, self-medication outside the healthcare system would put close contacts at grave risk of getting infected. After all, human-to-human transmission from infected cases to close contacts has been documented in China and other countries and even fourth-generation transmission has been recorded in Wuhan city, the epicentre of the disease outbreak in China.
Is the AYUSH Ministry aware of the kind of precautions that need to be taken while attending to people with the infection? Is it even aware that 16 healthcare workers who had been wearing all the mandatory protective gear while treating the infected cases fell ill themselves?
So when a passenger exhibiting symptoms suggestive of infection with the novel coronavirus is found at one of the 20 airports where thermal screening has been undertaken, will she be immediately quarantined and admitted to a hospital for further testing/treatment or will she be allowed to exercise her freedom to be treated at home with Unani medicines?
This should be reminder that the Health Ministry and AYUSH Ministry cannot afford to work at cross purposes.
పతంజలి కరోనా మందుకు బ్రేక్!
Jun 23, 2020, 19:22 IST
corona drug : Ministry of AYUSH asks for research data on
Patanjali Coronil - Sakshi
పూర్తి వివరాలు సమర్పించండి : ఆయుష్ మంత్రిత్వ శాఖ
అప్పటివరకూ ప్రచారాన్ని ఆపండి
సాక్షి, న్యూఢిల్లీ : కరోనా మహమ్మారి నివారణకు ఆయుర్వేద
మందును లాంచ్ చేసిన యోగా గురు రాందేవ్ నేతృత్వంలోని
పతంజలి సంస్థకు ఆదిలోనే అడ్డుకట్ట పడింది. ఆయుర్వేద
ఔషధం కరోనిల్ ప్రారంభానికి ముందు నిర్వహించిన పరిశోధనల
పూర్తి వివరాలు సమర్పించాలని కేంద్ర ఆయుష్ మంత్రిత్వ శాఖ
పతంజలి సంస్థను ఆదేశించింది. అంతేకాదు అప్పటివరకూ
ఎలాంటి ప్రచారాన్ని చేపట్టవద్దని కూడా మంత్రిత్వ శాఖ ఒక
పత్రికా ప్రకటనలో వెల్లడించింది. పతంజలి చెబుతున్న
అంశాలపై వాస్తవాలు, శాస్త్రీయ అధ్యయన వివరాలు మంత్రిత్వ
శాఖకు తెలియదని పేర్కొంది. ('కరోనిల్' 80 శాతం సక్సెస్ను
చూపించింది)
పతంజలి అట్టహాసంగా కరోనిల్ మందును ప్రారంభించిన కొన్ని
గంటల్లోనే ఆయుష్ మంత్రిత్వ శాఖ ఈ మందుకు సంబంధించి
కీలక ప్రకటన చేసింది. కోవిడ్-19 నివారణకు గాను పతంజలి
తయారు చేసిన ఆయుర్వేద మందును ఏ మోతాదులో, ఏయే
ఆసుపత్రిలలో పరిశీలించారు, సంబంధిత పరిశోధన ఫలితాల
తాజా డేటా, ఇనిస్టిట్యూషనల్ ఎథిక్స్ కమిటీ క్లియరెన్స్, సీటీఆర్ఐ
రిజిస్ట్రేషన్ వివరాలను తమకు అందించాలని మంత్రిత్వ శాఖ
కోరింది. వీటిని సమగ్రంగా పరిశీలించేంతవరకు ప్రచారాన్ని
ఆపాలని పతంజలి సంస్థను ఆదేశించింది. దీంతోపాటు కరోనిల్
తయారీకి మంజూరు చేసిన లైసెన్స్ కాపీలు, అనుమతి
వివరాలను అందించాలని మంత్రిత్వ శాఖ ఉత్తరాఖండ్
ప్రభుత్వాన్ని కోరింది. పతంజలి ప్రధాన కార్యాలయం హరిద్వార్లో
ఉంది, ఇది ఉత్తరాఖండ్ అధికార పరిధిలోకి వస్తుంది.
రాజస్థాన్ జైపూర్ నిమ్స్ వైద్యులతో పాటు పలువురు శాస్త్త్రవేత్తల
సహకారంతో 150కి పైగా ఔషధ మూలికలతో కరోనిల్ ఔషదాన్ని
రూపొందించామని పతంజలి సంస్థ ప్రకటించింది. క్లినికల్
కంట్రోల్ స్టడీ, క్లినికల్ కంట్రోల్ ట్రయల్ చేశాకే తాము కరోనిల్
మందును మార్కెట్లో విడుదల చేశామని రాందేవ్ వెల్లడించారు.
తమ మందు వాడిన కరోనా వైరస్ రోగులలో ఎక్కువ మంది 14
రోజుల్లో, దాదాపు 80 శాతం కోలుకున్నారని పతంజలి సహ
వ్యవస్థాపకుడు బాలకృష్ణ ప్రకటించిన సంగతి తెలిసిందే. కాగా
భారతదేశంలో 425,000 మందికి పైగా కరోనావైరస్ బారిన పడగా,
14,000 మంది మరణించారు. ప్రపంచవ్యాప్తంగా కరోనా బాధితుల
సంఖ్య తొమ్మిది మిలియన్లను దాటింది. మరణాల సంఖ్య 470,000
పైకి చేరుకుంది.
'కరోనిల్' 80 శాతం సక్సెస్ను చూపించింది
Jun 23, 2020, 12:20 IST
Ramdev To Launch 'Coronil' For Covid-19 Treatment Today - Sakshi
న్యూఢిల్లీ: కరోనా వ్యాక్సిన్ ను తయారు చేయడానికి ప్రపంచ దేశాలన్నీ అనేక ప్రయత్నాలు చేస్తున్నాయి. ఇప్పటికే 13 రకాల వ్యాక్సిన్లు మనుషులపై ప్రయోగించారు. మరో 120 కి పైగా సంస్థలు ఈ మందు తయారీలో నిమగ్నమయ్యాయి. తాజాగా యోగా గురువు బాబా రామ్దేవ్కు చెందిన పతంజలి ఆయుర్వేద సంస్థ కరోనా నివారణకు 'కరోనిల్' అనే ఆయుర్వేద ఔషదాన్ని కనుగొన్నట్లు ప్రకటించింది.
ఈ మేరకు పతంజలి యోగ్పీఠ్ సహవ్యవస్థాపకుడు ఆచార్య బాలకృష్ణ ట్విటర్ ద్వారా పేర్కొన్నారు. పతంజలి సంస్థ తయారుచేసిన ఔషదం 80 శాతం సక్సెస్ను చూపించినట్లు తెలిపారు. దీనికి సంబంధించిన పూర్తి వివరాలు మంగళవారం మధ్యాహ్నం హరిద్వార్లోని పతంజలి యోగ్పీఠ్లో ఏర్పాటు చేసే మీడియా సమావేశంలో వెల్లడించనున్నట్లు బాలకృష్ణ తన ట్విటర్ ఖాతాలో పేర్కొన్నారు. చదవండి: 'కరోనా నివారణకు ప్రత్యేక వ్యాక్సిన్'
Proud launch of first and foremost evidence-based ayurvedic medicine for #corona contagion, #SWASARI_VATI, #CORONIL, is scheduled for tomorrow at 12 noon from #Patanjali Yogpeeth Haridwar🙏🏻 pic.twitter.com/K7uU38Kuzl
— Acharya Balkrishna (@Ach_Balkrishna) June 22, 2020
